

Resource Summary Report

Generated by ASWG on Aug 3, 2026

Netherlands Brain Bank

RRID:SCR_013841

Type: Tool

Proper Citation

Netherlands Brain Bank (RRID:SCR_013841)

Resource Information

URL: <http://www.brainbank.nl>

Proper Citation: Netherlands Brain Bank (RRID:SCR_013841)

Description: A biomaterial supply resource which collects, stores, and disseminates diseased and healthy brain tissue. The Netherlands Brain Bank currently contains more than 3600 samples, and each sample includes a neuropathological report and donor medical history. The samples can additionally be matched with ante-mortem parameters and post-mortem parameters upon request. Sample types include cortex, spinal cord, cerebrospinal fluid, plasma, and DNA, among others. Database mining is available with a financial contribution.

Abbreviations: NBB

Resource Type: biomaterial supply resource, material resource

Keywords: biomaterial supply resource, brain, brain tissue, brain bank, diseased tissue, healthy tissue, FASEB list

Funding: Stichting MS Research ;
Vrienden Loterij ;
Stichting Parkinson Fonds ;
Hersenstichting Nederland Breinbekend Werk ;
Zabawas ;
private donations

Availability: Free, Available to the research community, The community can contribute to this resource, Some services require a contribution

Resource Name: Netherlands Brain Bank

Resource ID: SCR_013841

Record Creation Time: 20220129T080318+0000

Record Last Update: 20260801T191103+0000

Ratings and Alerts

No rating or validation information has been found for Netherlands Brain Bank.

No alerts have been found for Netherlands Brain Bank.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 158 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Rocha FM, et al. (2025) Mapping reactive astrogliosis in Parkinson's brain with astroglial tracers BU99008 and Deprenyl: New insights from a multi-marker postmortem study. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 21(2), e14488.

Theologidis V, et al. (2025) Bradykinesia and postural instability in a model of prodromal synucleinopathy with α -synuclein aggregation initiated in the gigantocellular nuclei. *Acta neuropathologica communications*, 13(1), 32.

Ciccaldello M, et al. (2025) A novel allosteric GCase modulator prevents Tau accumulation in GBA1WT and GBA1L444P/L444P cellular models. *Scientific reports*, 15(1), 17646.

Ivan T, et al. (2025) Aggregation-Dependent Epitope Sequence and Modification Fingerprints of Anti-A β Antibodies. *bioRxiv : the preprint server for biology*.

Vokali E, et al. (2025) Development of [18F]ACI-19626 as a first-in-class brain PET tracer for imaging TDP-43 pathology. *Nature communications*, 16(1), 9358.

Orr N, et al. (2025) Epstein-Barr virus and the immune microenvironment in multiple sclerosis: Insights from high-dimensional brain tissue imaging. *Proceedings of the National Academy of Sciences of the United States of America*, 122(11), e2425670122.

Weidling I, et al. (2025) hiPSC-neurons recapitulate the subtype-specific cell intrinsic nature of susceptibility to neurodegenerative disease-relevant aggregation. *Acta neuropathologica communications*, 13(1), 108.

Wesseling A, et al. (2025) Amygdalar and hippocampal volume loss in limbic-predominant age-related TDP-43 encephalopathy. *Brain : a journal of neurology*, 148(11), 3913.

Patel R, et al. (2025) FABP7 is increased in progressive multiple sclerosis and induces a pro-inflammatory phenotype in monocytes through a glycolytic switch. *Nature*

communications, 16(1), 6049.

van Wetering J, et al. (2025) Limbic Alzheimer's co-pathology in multiple system atrophy is associated with cognitive impairment and diagnostic inaccuracy. *Acta neuropathologica*, 150(1), 30.

Müller-Schiffmann A, et al. (2025) Oxidized MIF is an Alzheimer's disease drug target relaying external risk factors to tau pathology. *Cell reports. Medicine*, 102520.

Mahul-Mellier AL, et al. (2025) Differential role of C-terminal truncations on alpha-synuclein pathology and Lewy body formation. *NPJ Parkinson's disease*, 11(1), 261.

Frigerio I, et al. (2025) Synaptic enrichment of pSer129 alpha-synuclein correlates with dopaminergic denervation in early-stage Parkinson's disease. *Nature communications*, 16(1), 6630.

Schneider Y, et al. (2025) Vimentin network dysregulation mediates neurite deficits in SNCA duplication Parkinson's patient-derived midbrain neurons. *Science advances*, 11(23), eadq2742.

Fagiani F, et al. (2025) Spatially-restricted inflammation-induced senescent-like glia in multiple sclerosis and patient-derived organoids. *Nature communications*, 16(1), 8477.

Nguyen TB, et al. (2025) Aberrant splicing in Huntington's disease accompanies disrupted TDP-43 activity and altered m6A RNA modification. *Nature neuroscience*, 28(2), 280.

Bouwman MMA, et al. (2025) Hippocampal subfields: volume, neuropathological vulnerability and cognitive decline in Alzheimer's and Parkinson's disease. *Alzheimer's research & therapy*, 17(1), 121.

Wihan J, et al. (2025) Alpha synuclein-mediated cytoskeletal dysfunction impairs myelination in human oligodendrocytes. *Acta neuropathologica*, 150(1), 33.

Reijner N, et al. (2025) Clinical phenotypes of Alzheimer's disease: investigating atrophy patterns and their pathological correlates. *Alzheimer's research & therapy*, 17(1), 93.

Murphy KB, et al. (2025) CHAS infers cell type-specific signatures in bulk brain histone acetylation studies of neurological and psychiatric disorders. *Cell reports methods*, 5(5), 101032.